I don’t see the issue really though, if the $20 part still produces something more likely to get through the billion dollar parts what’s the problem ?
Re-ranking pre-clinical leads is the scientific equivalent of that old saying about opinions.
There is no objective function you can optimize your way to a drug discovery machine, let alone a fundamental understanding of how the underlying system works.